SCHEMBL23536130

SCHEMBL23536130

Nc1ccccc1N1CC2(C1)CN(c1ccc(Cl)cc1F)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 2/20 0.41
KEAP1 Q14145 1/20 0.40
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
GFER P55789 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
DRD4 P21917 1/20 0.39
GRM2 Q14416 1/20 0.39
ADRA2C P18825 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.35
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932056 1.00 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL24628429 0.91 ALDH1A1 (0.40) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL29772888 0.91 ALDH1A1 (0.40) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL24628435 0.89 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL29772891 0.89 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL21261239 0.88 POLB (0.54) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL23536146 0.78 MAPT (0.53) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL29931960 0.78 MAPT (0.53) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL23536467 0.75 DRD4 (0.36) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL21261238 0.75 DRD4 (0.41) ALDH1A1LMNAKDM4EHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 ALDH1A1 3737/4885LMNA 3324/4885KDM4E 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.